Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems

doi:10.1016/0006-8993(95)01241-9

Brain Research

Volume 708, Issues 1–2, 5 February 1996, Pages 38-44

https://doi.org/10.1016/0006-8993(95)01241-9 Get rights and content

Abstract

Glutamate agonists have been shown to stimulate striatal dopamine release, but less is known about dopamine-glutamate interactions at the receptor level. We treated rats with 0.3, 1.0, or 3.0 mg/kg of MK-801, an NMDA antagonist, daily for 1 week and, using in situ hybridization, measured dopamine receptor rnRNA levels in cortical and subcortical structures. MK-801 caused a significant increase of D₁ and D₂ mRNA in the dorsal and ventral striatum, a significant decrease of D₃ mRNA in the nucleus accumbens, and a significant decrease of D₁ mRNA in the limbic cortex. Dopamine autoreceptor expression, reflected by D₂ mRNA in the midbrain, was increased in the ventral tegmental area, but not in the substantia nigra. Thus, MK-801 appears to differentially regulate the mesocorticolimbic and nigrostriatal dopamine systems.

Reference (53)

Arias-MontanoJ.A. et al.
Glutamate stimulation of tyrosine hydroxylase is mediated by NMDA receptors in the rat striatum
Brain Res.
(1992)
CarboniE. et al.
Amphetamine, cocaine, phencyclidine and nomiphensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats
Neuroscience
(1989)
CarlssonM. et al.
Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease
Trends Neurosci.
(1990)
DesceJ.M. et al.
Opposite presynaptic regulations by glutamate through NMDA receptors of dopamine synthesis and release in rat striatal synaptosomes
Brain Res.
(1994)
GiorguieffM. et al.
Presynaptic effect ofl-glutamic acid on the release of dopamine in rat striatal slices
Neurosci. Lett.
(1977)
GuanX.-M. et al.
Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release
Brain Research Bull.
(1989)
ImperatoA. et al.
Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats
Brain Res.
(1990)
JonesC.A. et al.
Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro
Eur. J. Pharmacol.
(1993)
KashiharaK. et al.
Effect of MK-801 on endogenous dopamine release in vivo
Brain Research
(1990)
KeefeK.A. et al.
Extracellular dopamine in striatum: influence of nerve impulse activity in medial forebrain bundle and local glutamatergic input
Neuroscience
(1992)

KissJ.P. et al.

NMDA receptors are not involved in the MK-801-induced increase of striatal dopamine release in rat: a microdialysis study

Brain Res.

(1994)

KobayashiK. et al.

An increase in the in vivo binding of [3H]SCH-23390 induced by MK-801 in the mouse striatum

Neuropharmacology

(1993)

LiljequistS. et al.

Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice

Eur. J. Pharmacol.

(1991)

MansourA. et al.

A comparison of Dl receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques

Neuroscience

(1991)

Meador-WoodruffJ.H. et al.

Distribution of D5 dopamine receptor mRNA in rat brain

Neurosci. Lett.

(1992)

MoghaddamB. et al.

Effect ofl-glutamate on the release of straital dopamine: in vivo dialysis and electrochemical studies

Brain Res.

(1990)

QinZ.-H. et al.

D₂ Dopamine receptor messenger RNA is altered to a greater extent by blockade of glutamate receptors than by blockade of dopamine receptors

Neuroscience

(1994)

RansomR.W. et al.

Glycine modulation of NMDA-evoked release of [3H]acetylcholine and [3H]dopamine from rat striatal slices

Neurosci. Lett.

(1989)

RobertsP.J. et al.

Effects ofl-glutamate and related amino-acids upon the release of 3H-dopamine from rat striatal slices

Brain Res.

(1978)

RosalesM.G. et al.

Activation of subthalamic neurons produces NMDA receptor-mediated dendritic dopamine release in substantia nigra pars reticulata: a microdialysis study in the rat

Brain Res.

(1994)

WedzonyK. et al.

MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D₁ receptors

Brain Res.

(1993)

WhittonP.S. et al.

N-Methyld-aspartate receptors modulate extracellular dopamine concentration and metabolism in rat hippocampus and striatum in vivo

Brain Res.

(1994)

ArenedaR. et al.

Modulation of dendritic release of dopamine by N-methyl-daspartate receptors in rat substantia nigra

J. Neurochem.

(1989)

BowyerJ.F. et al.

Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes

J. Pharmacol. Exp. Ther.

(1984)

BowyerJ.F. et al.

A further evaluation of the effects of K+ depolarization on glutamate-evoked [3H]dopamine release from striatal slices

J. Pharmacol. Exp. Ther.

(1992)

CaiN.S. et al.

Heterogeneity of N-methyl-d aspartate receptors regulating the release of dopamine and acetylcholine from striatal slices

J. Neurochem.

(1991)

Cited by (41)

The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats
2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Citation Excerpt :
The rewarding/reinforcing effects of amphetamine are mediated via stimulation of the mesocorticolimbic dopamine system (Fleckenstein et al., 2007), although activation of other neurotransmitters, including glutamate (Gass and Olive, 2008), may also be involved. Interestingly, amphetamine is a modulator of D2 dopamine receptors (Amit and Smith, 1992; Fletcher, 1998; Ginovart et al., 1999; Levy et al., 1988; Seeman et al., 2002) and D2 receptors were reported to interact with some of the glutamate receptors (David and Abraini, 2001; Healy and Meador-Woodruff, 1996; Rouillon et al., 2008; Wang et al., 2012). Thus, an interaction between these two systems may have an impact on amphetamine effects.
Chronic amphetamine use results in anxiety-like states after drug cessation. The aim of the study was to determine a role of ionotropic and metabotropic glutamate receptor ligands in amphetamine-evoked withdrawal anxiety in the elevated plus-maze test in rats. In our study memantine (8 and 12 mg/kg), a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist did not reduce amphetamine withdrawal anxiety. Acamprosate (NMDA and metabotropic glutamate 5 receptor (mGluR5) antagonist) at the dose 200 and 400 mg/kg showed anxiolytic-like effect, thus increasing the percent of time spent in open arms and a number of open arm entries. mGluR5 selective antagonist, MTEP (3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine hydrochloride) and mGluR2/3 agonist, LY354740 (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid), caused effects similar to acamprosate at doses 1.25–5 mg/kg and 2.5–5 mg/kg, respectively. None of the glutamate ligands influenced locomotor activity of rats when given to the saline-treated group. Taking into account the positive correlation between amphetamine withdrawal-induced anxiety and relapse to amphetamine taking, our results suggest that modulation of mGluRs may prevent relapse to amphetamine and might pose a new direction in amphetamine abuse therapy.
Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis
2013, Neuropharmacology
Citation Excerpt :
Theoretically, the NMDAR-hypofunction hypothesis provides the unique possibility to integrate nearly all distinct pieces of evidence from schizophrenia research regarding the involvement of different neurotransmitter systems. The link to the dopamine hypothesis is demonstrated by the finding that dopamine receptor expression is altered in rats after treatment with the irreversible NMDAR-antagonist MK801 (Healy and Meador-Woodruff, 1996). Moreover, dopaminergic neurons increase their firing rates upon intravenous treatment with MK801 (Zhang et al., 1992).
It is postulated that disruptions of glutamatergic signalling may underlie the pathophysiology of psychosis and schizophrenia. A strong body of evidence indicates that antagonism of the N-methyl-d-aspartate receptor (NMDAR) leads to similar molecular, cellular, cognitive and behavioural changes in rodents and/or humans to those that have been identified to occur in psychosis. One of the main loci of change appears to comprise the hippocampus, raising the question as to whether changes in hippocampal glutamatergic transmission may drive changes in GABAergic and dopaminergic-mediated signalling in schizophreniform diseases. NMDAR antagonists such as MK801, PCP and ketamine all elicit similar psychosis-related effects, with MK801 inducing the most potent psychotomimetic reactions. Treatment with MK801 is associated with a loss of hippocampal synaptic plasticity, hippocampus-dependent learning and cognitive deficits. These findings have raised the question as to whether targeting the NMDA receptors or its modulators could prove an effective strategy in treatment of psychosis and schizophrenia. Specifically, the otherwise untreatable negative and cognitive symptoms of schizophrenia currently comprise the highest research priority. A single injection with MK801 has been used to emulate first-episode psychosis in animals. This treatment induces both psychosis-related acute effects but interestingly also persisting consequences, which might be more sensitive as indicators of drug efficacy. Here, we review the current status of the field with regard to the MK801 animal model of first-episode psychosis and its relevance for the glutamate hypothesis of schizophrenia. Furthermore, we argue that synaptic plasticity may be a better assay for assessing novel schizophrenia therapeutics than behavioural evaluation.
This article is part of the Special Issue entitled ‘Glutamate Receptor-Dependent Synaptic Plasticity’.
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism
2007, Schizophrenia Research
Some behavioral symptoms and neuropathological features of schizophrenia, like alterations of local GABAergic interneurons, could be emulated in an animal model of psychosis based on prolonged low-dose exposure to N-methyl-d-aspartate (NMDA) receptor antagonists, e.g. MK-801. Employing this model, we examined distinct subpopulations of GABAergic interneurons within the hippocampus and prefrontal cortex. Compared to saline control, animals receiving MK-801 exhibited a decreased density of hippocampal parvalbumin-positive interneurons. A co-administration of the antipsychotic drug haloperidol ameliorated this effect of MK-801 on PV⁺ interneurons in the hippocampus, but led to a marked reduction of PV immunoreactivity in the prefrontal cortex, when comparing with saline, MK-801 or haloperidol treatment alone. Neither calretinin immunoreactivity nor nicotinamide adenine dinucleotide phosphate (NADPH)-diaphorase staining, representing neuronal nitric oxide synthase activity mostly detectable in interneurons, was altered by either treatment. With special reference to the hippocampus, these data show that a prolonged application of low-dose NMDA receptor antagonist could, in part, mimic some neuropathologic findings in human schizophrenia, thus strengthening the idea that (sub-) chronic NMDA receptor antagonism in animals is a viable approach in mimicking aspects of schizophrenia. Moreover, this study provides further evidence for regional differences in the response of GABAergic interneurons to NMDA receptor antagonism and antipsychotic treatment.
Clozapine but not haloperidol treatment reverses sub-chronic phencyclidine-induced disruption of conditional discrimination performance
2006, Behavioural Brain Research
Abusers of phencyclidine (PCP) often present with a symptom profile similar to that exhibited by schizophrenic patients. Animal models utilising such psychotomimetics are currently informing research into the condition. Accumulating evidence suggests that a central cognitive deficit in schizophrenia is the inability to use task-setting cues to guide goal directed behaviour and that this ability is mediated by prefrontal dopamine (DA). The current study used the non-competitive NMDA antagonist phencyclidine (PCP) and Haloperidol (typical antipsychotic) and Clozapine (atypical antipsychotic) in order to further investigate the influence of DAergic manipulation on a task that requires the use of conditional information to inform goal-directed performance. An instrumental conditional discrimination task was employed in which rats learn to respond appropriately according to the presence of specific auditory conditional stimuli. Probe test 1 showed impaired conditional discrimination performance following sub-chronic PCP administration (seven twice-daily injection protocol) compared to control which was reversed by acute treatment with clozapine (5 mg/kg) but not haloperidol (0.1 mg/kg) both administered 60 min pre-test. Probe test 2 (8 days post-treatment) showed enduring deficits to conditional discrimination performance that were again reversed by clozapine but not haloperidol (injection procedures as above). These results show that tasks dependent upon conditional relationships are particularly sensitive to manipulation of DAergic systems as prolonged treatment with PCP has been shown to selectively reduce prefrontal cortex (PFC) DA activity and treatment with clozapine (known to ameliorate cognitive deficits) but not haloperidol has been shown to selectively restore PFC DA levels.
Repeated subchronic exposure to phencyclidine elicits excessive atypical grooming in rats
2006, Behavioural Brain Research
Self-grooming in rodents is stereotypically sequenced and naturally occurs after arousal, novelty, or stress. Grooming expression and syntax resulting from stressful and appetitive conditions were assessed in male Long Evans rats treated daily with 10 mg/kg of phencyclidine (PCP) for 15 days. Approximately 20 h after the 1st, the 8th, and/or the 15th injection, grooming was induced with water sprays, a loud sound, or smearing food. Behaviors expressed during the seconds or minutes that followed induction were videotaped and codified. Results showed that subchronic treatment with PCP amplified the grooming response in all stressful and appetitive conditions, but provoked a disorganization of grooming sequences only under the stressful, water condition. Thus, PCP enhanced grooming expression indiscriminately. However, this behavior had to serve both hygienic and stress managing purposes in order for chain sequencing to become disorganized as a consequence of drug treatment. These results suggest that the detailed examination of grooming expression and organization is an appropriate tool to measure stress-induced behavioral sensitization and motor functions in animal models of neuropsychiatric disorders such as schizophrenia.
The role of MK-801 in sensitization to stimulants
2001, Brain Research Reviews
Behavioral responses to stimulants can be progressively and persistently enhanced by their repeated administration. This phenomenon, called behavioral sensitization, may underlie substance abuse, psychosis, recurrence in bipolar disorder, or other psychiatric problems. A growing body of work has implicated excitatory amino acid systems in behavioral sensitization. Most of the evidence for a role of excitatory amino acids has come from experiments demonstrating prevention of sensitization by excitatory amino acid antagonists, especially the noncompetitive NMDA receptor antagonist MK-801. Results of studies with MK-801 have varied, however, leading to conflicting interpretations of its relationship to behavioral sensitization. This paper critically discusses the design of experiments that have used MK-801, and interprets data from these experiments in terms of the two leading explanations for the role of MK-801: 1) that sensitization is an example of the family of plastic events that require excitatory amino acid transmission or 2) that interoceptive cues associated with MK-801 lead to state-dependent learning that modifies sensitization because, in essence, the animal does not recognize the stimulant as the same drug if it is given in close association with MK-801. Based on conflicting reports on effects of MK-801, we propose 1) strategies for distinguishing components of MK-801’s effects on responses to stimulants, 2) a model that is a hybrid of the two interpretations of its effects on sensitization, and 3) experimental strategies for testing this model.

View all citing articles on Scopus

View full text

Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems

Abstract

Brain Res.

Neuroscience

Trends Neurosci.

Brain Res.

Neurosci. Lett.

Brain Research Bull.

Brain Res.

Eur. J. Pharmacol.

Brain Research

Neuroscience

Brain Res.

Neuropharmacology

Eur. J. Pharmacol.

Neuroscience

Neurosci. Lett.

Brain Res.

Neuroscience

Neurosci. Lett.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Modulation of dendritic release of dopamine by N-methyl-daspartate receptors in rat substantia nigra

J. Neurochem.

Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes

J. Pharmacol. Exp. Ther.

A further evaluation of the effects of K+ depolarization on glutamate-evoked [3H]dopamine release from striatal slices

J. Pharmacol. Exp. Ther.

Heterogeneity of N-methyl-d aspartate receptors regulating the release of dopamine and acetylcholine from striatal slices

J. Neurochem.